<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049035</url>
  </required_header>
  <id_info>
    <org_study_id>MET39</org_study_id>
    <secondary_id>UTN: U1111-1112-2593</secondary_id>
    <nct_id>NCT01049035</nct_id>
  </id_info>
  <brief_title>A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers</brief_title>
  <official_title>Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Infants and Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent
      Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW
      Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent
      meningococcal vaccine in the population with the highest incidence of disease.

      Objectives:

        -  To describe the safety profile of MenACYW Conjugate vaccine administered at 5 different
           schedules and concomitantly with routine pediatric vaccinations.

        -  To describe the immunogenicity profile of MenACYW Conjugate vaccine administered at 5
           different schedules and concomitantly with routine pediatric vaccinations.

        -  To describe the immunogenicity profiles of selected licensed pediatric vaccines
           (Pentacel, Prevnar, M-M-RII, and Varivax) when administered either concomitantly with or
           without MenACYW Conjugate vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants received study vaccinations beginning at age 2, 6, 12, or 15 months, depending
      on the assigned schedule in their randomized groups. All participants underwent safety and
      immunogenicity assessments according to the schedule for their assigned group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2009</start_date>
  <completion_date type="Actual">February 13, 2012</completion_date>
  <primary_completion_date type="Actual">February 13, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an Serum Bactericidal Assay (SBA) Using Human Complement (SBA-HC) Titer Greater or Than Equal to (≥) 1:8 and ≥1:4: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-protocol Population (PPP)</measure>
    <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. The PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not receive the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provide a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Serum Bactericidal Assay Using Human Complement Titer ≥1:8 and ≥1:4: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Groups 2 and 7: at the age of 16 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not received the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provided a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement Titer ≥1:8 and ≥1:4: Group 5 - Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not received the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provided a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-HC Pre-booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-booster titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-booster titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-HC Pre-vaccination Titer ≥1:8 Who Then Achieved ≥4-fold Rise in SBA-HC Titer After Vaccination: Group 5 - Per-Protocol Population</measure>
    <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-vaccination titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-vaccination titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post-vaccination) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-HC Pre-booster Titer Less Than (&lt;) 1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC After Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-booster titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-booster titer was &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-HC Pre-Vaccination Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Vaccination: Group 5 - Per-Protocol Population</measure>
    <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Percentage of participants with pre-vaccination titer &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post vaccination) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers (GMTs): Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</measure>
    <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months, Group 3: at the age of 5 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Groups 2 and 7: at the age of 16 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers: Group 5 - Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With ≥4-fold Rise in SBA-HC Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months), Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Percentage of participants with ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in SBA-HC Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3 and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months), Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Titer ≥1:8 and ≥1:128: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</measure>
    <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-BR Titer ≥1:8 and ≥1:128: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Groups 2 and 7: at the age of 16 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-BR Titer ≥1:8 and ≥1:128: Group 5 - Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-BR Pre-Booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-booster titer was defined as titer value reported before the age of 12 months. Percentage of participants whose pre-booster titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-BR Pre-Vaccination Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Vaccination: Group 5 - Per-Protocol Population</measure>
    <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants whose pre-vaccination titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer at the age of Month 13 (i.e. 30-days post vaccination at Month 12) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-BR Pre-Booster Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titers After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-booster titer was defined as titer value reported before the age of 12 months. Percentage of participants whose pre-booster titer was &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With SBA-BR Pre-Vaccination Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Vaccination: Group 5 - Per-Protocol Population</measure>
    <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-vaccination titer was defined as titer value reported before the age of 12 months. Percentage of participants with pre-vaccination titer &lt;1:8 and who achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post-vaccination) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With ≥4-fold Rise in SBA-BR Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post booster vaccination (i.e., at the age of 13 months); Group 2: 30 days post booster vaccination (i.e., at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants with ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP which was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</measure>
    <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Group 2 and 7: at the age of 16 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers in Group 5: Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise in Serum Bactericidal Assay Using Baby Rabbit Complement Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, and 4: 30 days post booster vaccination at the age of 12 months (i.e., at the age of 13 months); Group 2: 30 days post booster vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
    <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants with GMFR in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Titer/Concentration to All the Antigens Contained in Pentacel Vaccines: Groups 1, 2, 4, 6, and 7 - Primary Series Per-Protocol Population</measure>
    <time_frame>At the age of 7 months</time_frame>
    <description>Pentacel vaccine is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined). Antibody titer to all antigens contained in pentacel vaccines (i.e., Anti-PRP, Anti-Diptheria, Anti-pertussis [pertussis toxoid [PT], pertactin [PRN], filamentous hemagglutinin [FHA], and fimbriae [FIM]], Anti-poliovirus [anti-poliovirus Type 1, Type 2 and Type 3] and anti-tetanus) were reported. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Titer/Concentration to All Antigens Contained in Pentacel Vaccines: Groups 2 and 7 - Booster Per-Protocol Population</measure>
    <time_frame>At the age of 16 months</time_frame>
    <description>Pentacel vaccine is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined). Antibody titer to all antigens contained in pentacel vaccines (i.e., Anti-PRP, Anti-Diptheria, Anti-pertussis [PT, PRN, FHA, and FIM], Anti-poliovirus [anti-poliovirus Type 1, Type 2, and Type 3], and Anti-tetanus) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Groups 1, 2, 4, 6, and 7 - Primary Series Per-Protocol Population</measure>
    <time_frame>At the age of 7 months</time_frame>
    <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F, and 23F is reported. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL and ≥1.0 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Groups 1, 3, 4, and 6 - Booster Series Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL and ≥1.0 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F and 23F is reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL and ≥1.0 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Group 5- Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL and ≥1.0 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F and 23F is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Antibodies to All Antigens Contained in M-M-RII and VARIVAX Vaccines: Groups 1 and 6 - Booster Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Antibodies responses were measured by ELISA. Antigens contained in M-M-RII: Measles, Mumps, and Rubella and in Varivax®: Varicella. Percentage of participants with anti-measles, anti-mumps, anti-rubella, and anti-varicella antibody concentration that met the respective mentioned criterion were reported: Measles: ≥255 milli-International Units per milliliter (mIU/mL); Mumps: ≥10 Antibody units per milliliter (AbU/mL); Rubella: ≥10 International Units per milliliter (IU/mL); Varicella: ≥5 glycoprotein based enzyme-linked immunosorbent assay (gpELISA) unit/mL. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Antibody Titers to Tetanus Toxoid: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</measure>
    <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
    <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age. Here, '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations of Antibodies to Tetanus Toxoid: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</measure>
    <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months, Group 2 and 7: at the age of 16 months</time_frame>
    <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months. Here, '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations of Antibodies to Tetanus Toxoid: Group 5 - Per-Protocol Population</measure>
    <time_frame>At the age of 13 months</time_frame>
    <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection Site Reactions</measure>
    <time_frame>Within 7 days post any vaccination</time_frame>
    <description>Solicited injection site reactions: tenderness/pain, erythema, and swelling and were planned to be collected and reported for each vaccine separately and not planned to be collected for Rotavirus vaccine. Here, '0' in number analyzed field for MenACYW categories signifies no participant were evaluable because in Groups 6 and 7 MenACYW vaccine was not administered; for Group 5, '0' in number analyzed field signifies safety data collection was not planned for Pentacel and Hepatitis-B vaccines; for Groups 2 and 7, '0' in number analyzed field signifies safety data collection was not planned for M-M-RII and VARIVAX vaccines, as pre-specified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic Reactions</measure>
    <time_frame>Within 7 days post any vaccination</time_frame>
    <description>An solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the electronic case report form (eCRF). Systemic AEs were all AEs that were not injection site reactions. They, therefore, include systemic manifestations as well as localized or topical manifestations that were not associated with the vaccination site. Solicited systemic reactions included Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events</measure>
    <time_frame>Within 30 days post any vaccination</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of symptom and/or onset post-vaccination. These included both serious and non-serious events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Immediate Unsolicited AE</measure>
    <time_frame>Within 30 minutes post any vaccination</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of symptom and/or onset post-vaccination. These included both serious and non-serious events. Immediate Unsolicited AE were AEs reported within 30 minutes of vaccine administration.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcal Infection</condition>
  <arm_group>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 months (at the time of enrollment) received Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein (MenACYW) Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate</intervention_name>
    <description>0.5 milliliter (mL), Intramuscular (IM) injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <other_name>TetraMen-T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)</intervention_name>
    <description>0.5 mL, IM injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <other_name>Pentacel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live</intervention_name>
    <description>0.5 mL, Subcutaneous (SC) injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella Virus Vaccine Live</intervention_name>
    <description>0.5 mL, SC injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <other_name>Varivax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)</intervention_name>
    <description>0.5 mL, IM injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <other_name>Prevnar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)</intervention_name>
    <description>0.5 mL, IM injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <other_name>Prevnar 13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus Vaccine</intervention_name>
    <description>oral</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <other_name>RotaTeq/ROTARIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccine</intervention_name>
    <description>0.5 mL, IM injection</description>
    <arm_group_label>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</arm_group_label>
    <arm_group_label>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</arm_group_label>
    <arm_group_label>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</arm_group_label>
    <arm_group_label>Group 5: MenACYW Conjugate Vaccine: Month 12</arm_group_label>
    <arm_group_label>Group 6: Control: 2, 4, 6, and 12 Months</arm_group_label>
    <arm_group_label>Group 7: Control: 2, 4, 6, 12, and 15 Months</arm_group_label>
    <other_name>Engerix-B/Recombivax-HB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Groups 1, 2, 3, 6, and 7: Aged 42 to 89 days on the day of inclusion; Group 4: Aged 6
             months (180 days ± 14 days) on the day of inclusion; Group 5: Aged 12 months (365 days
             + 14 days) on the day of inclusion.

          -  Born at full term of pregnancy (greater than or equal to [≥] 37 weeks) and with a
             birth weight ≥2.5 kilogram (kg).

          -  Informed consent form had been signed and dated by the parent or other legally
             acceptable representative.

          -  Participant and parent/guardian were able to attend all scheduled visits and to be
             complied with all trial procedures.

          -  Group 4 only: Prior receipt of Pentacel and Prevnar at 2 and 4 months; 1 or 2 doses of
             rotavirus vaccine; and 2 or 3 previous doses of hepatitis B vaccine.

        Group 5 only: Prior receipt of Pentacel and Prevnar at 2, 4, and 6 months; 2 or 3 doses of
        rotavirus vaccine; and 3 previous doses of hepatitis B vaccine.

        Exclusion Criteria:

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or medical procedure in the 4 weeks preceding the first trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination, with
             the exception of influenza vaccine, which may be received 14 days before or after
             MenACYW Conjugate vaccine.

          -  Previous vaccination against meningococcal disease with either the trial vaccine or
             another vaccine.

          -  Receipt of blood or blood-derived products in the past 30 days, which might interfere
             with assessment of the immune response.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy; or
             long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2
             consecutive weeks).

          -  Known personal or maternal seropositivity for human immunodeficiency virus (HIV),
             hepatitis B vaccine, or hepatitis C, as reported by the parent/guardian.

          -  History of meningococcal infection, confirmed either clinically, serologically, or
             microbiologically.

          -  At high risk for meningococcal infection during the trial.

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccines used in the trial or to a vaccine containing
             any of the same substances.

          -  Thrombocytopenia, as reported by the parent/guardian.

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination.

          -  History of seizures.

          -  Personal or family history of Guillain-Barré Syndrome (GBS).

          -  Chronic illness that, in the opinion of the investigator, was at a stage where it
             might interfere with trial conduct or completion.

        Temporary contraindications were resolved before vaccination:

          -  Febrile illness (temperature ≥38.0 degree Celsius [≥100.4 degree Fahrenheit]) or
             moderate or severe acute illness/infection (according to investigator judgment) on the
             day of vaccination.

          -  Group 5 only: Receipt of oral or injected antibiotic therapy within the 72 hours prior
             to the study blood draw. Topical antibiotics or antibiotic drops were not included in
             this exclusion criterion. (Note: This did not applied to the other groups at this
             time, as they did not have a blood draw within 30 days of the initial visit.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>365 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clyde</city>
        <state>North Carolina</state>
        <zip>28721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>May 19, 2020</results_first_submitted>
  <results_first_submitted_qc>May 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <disposition_first_submitted>April 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2013</disposition_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcal Infection</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Tetravalent Meningococcal Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Participant level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted from 16 December 2009 to 13 February 2012 at 21 active sites in the United States.</recruitment_details>
      <pre_assignment_details>A total of 580 participants who met all inclusion and none of the exclusion criteria were enrolled and randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein (MenACYW) Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
          <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
          <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
        </group>
        <group group_id="P6">
          <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
        </group>
        <group group_id="P7">
          <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other adverse event (AE)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with the protocol</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal not due to an AE</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
          <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
          <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
        </group>
        <group group_id="B6">
          <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
        </group>
        <group group_id="B7">
          <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="75"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="54"/>
            <count group_id="B8" value="580"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.19" spread="0.261"/>
                    <measurement group_id="B2" value="2.20" spread="0.259"/>
                    <measurement group_id="B3" value="2.23" spread="0.296"/>
                    <measurement group_id="B4" value="6.23" spread="0.148"/>
                    <measurement group_id="B5" value="12.4" spread="0.136"/>
                    <measurement group_id="B6" value="2.18" spread="0.217"/>
                    <measurement group_id="B7" value="2.20" spread="0.268"/>
                    <measurement group_id="B8" value="4.04" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Serum Bactericidal Assay (SBA) Using Human Complement (SBA-HC) Titer Greater or Than Equal to (≥) 1:8 and ≥1:4: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-protocol Population (PPP)</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. The PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not receive the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provide a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
        <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
        <population>Primary series PPP. 'Number analyzed’=number of participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Serum Bactericidal Assay (SBA) Using Human Complement (SBA-HC) Titer Greater or Than Equal to (≥) 1:8 and ≥1:4: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-protocol Population (PPP)</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. The PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not receive the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provide a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
          <population>Primary series PPP. 'Number analyzed’=number of participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 5 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="83.1" lower_limit="72.9" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="74.0" lower_limit="62.8" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 7 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="69.9" upper_limit="88.7"/>
                    <measurement group_id="O2" value="80.2" lower_limit="69.9" upper_limit="88.3"/>
                    <measurement group_id="O4" value="75.9" lower_limit="62.8" upper_limit="86.1"/>
                    <measurement group_id="O5" value="15.9" lower_limit="6.6" upper_limit="30.1"/>
                    <measurement group_id="O6" value="25.7" lower_limit="12.5" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="60.0" upper_limit="81.2"/>
                    <measurement group_id="O2" value="66.7" lower_limit="55.3" upper_limit="76.8"/>
                    <measurement group_id="O4" value="62.1" lower_limit="48.4" upper_limit="74.5"/>
                    <measurement group_id="O5" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O6" value="2.9" lower_limit="0.1" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 5 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="97.4" lower_limit="90.9" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="94.8" lower_limit="87.2" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 7 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="89.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="93.8" lower_limit="86.2" upper_limit="98.0"/>
                    <measurement group_id="O4" value="90.2" lower_limit="79.8" upper_limit="96.3"/>
                    <measurement group_id="O5" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O6" value="17.1" lower_limit="6.6" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="84.0" upper_limit="97.1"/>
                    <measurement group_id="O2" value="92.6" lower_limit="84.6" upper_limit="97.2"/>
                    <measurement group_id="O4" value="88.5" lower_limit="77.8" upper_limit="95.3"/>
                    <measurement group_id="O5" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O6" value="2.9" lower_limit="0.1" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 5 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="83.1" lower_limit="72.9" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="75.3" lower_limit="64.2" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 7 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="91.0" upper_limit="99.7"/>
                    <measurement group_id="O2" value="93.8" lower_limit="86.2" upper_limit="98.0"/>
                    <measurement group_id="O4" value="29.5" lower_limit="18.5" upper_limit="42.6"/>
                    <measurement group_id="O5" value="8.9" lower_limit="2.5" upper_limit="21.2"/>
                    <measurement group_id="O6" value="11.4" lower_limit="3.2" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="80.8" upper_limit="95.5"/>
                    <measurement group_id="O2" value="91.4" lower_limit="83.0" upper_limit="96.5"/>
                    <measurement group_id="O4" value="24.6" lower_limit="14.5" upper_limit="37.3"/>
                    <measurement group_id="O5" value="6.7" lower_limit="1.4" upper_limit="18.3"/>
                    <measurement group_id="O6" value="5.7" lower_limit="0.7" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 5 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="92.2" lower_limit="83.8" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="84.4" lower_limit="74.4" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 7 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="93.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.8" lower_limit="93.3" upper_limit="100.0"/>
                    <measurement group_id="O4" value="42.6" lower_limit="30.0" upper_limit="55.9"/>
                    <measurement group_id="O5" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O6" value="11.4" lower_limit="3.2" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="87.4" upper_limit="98.6"/>
                    <measurement group_id="O2" value="96.3" lower_limit="89.6" upper_limit="99.2"/>
                    <measurement group_id="O4" value="24.6" lower_limit="14.5" upper_limit="37.3"/>
                    <measurement group_id="O5" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O6" value="2.9" lower_limit="0.1" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Serum Bactericidal Assay Using Human Complement Titer ≥1:8 and ≥1:4: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not received the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provided a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Groups 2 and 7: at the age of 16 months</time_frame>
        <population>Booster PPP. Here, 'Number analyzed'=number of participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Serum Bactericidal Assay Using Human Complement Titer ≥1:8 and ≥1:4: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not received the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provided a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Booster PPP. Here, 'Number analyzed'=number of participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 13 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="85.9" upper_limit="98.9"/>
                    <measurement group_id="O3" value="96.4" lower_limit="87.5" upper_limit="99.6"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="28.0" lower_limit="12.1" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 13 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="85.9" upper_limit="98.9"/>
                    <measurement group_id="O3" value="94.5" lower_limit="84.9" upper_limit="98.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 16 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="96.9" lower_limit="89.2" upper_limit="99.6"/>
                    <measurement group_id="O6" value="30.8" lower_limit="14.3" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 16 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="93.8" lower_limit="84.8" upper_limit="98.3"/>
                    <measurement group_id="O6" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 13 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="85.9" upper_limit="98.9"/>
                    <measurement group_id="O3" value="94.5" lower_limit="84.9" upper_limit="98.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="30.8" lower_limit="14.3" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 13 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="85.9" upper_limit="98.9"/>
                    <measurement group_id="O3" value="90.9" lower_limit="80.0" upper_limit="97.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 16 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="98.5" lower_limit="91.7" upper_limit="100.0"/>
                    <measurement group_id="O6" value="34.6" lower_limit="17.2" upper_limit="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 16 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="96.9" lower_limit="89.3" upper_limit="99.6"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 13 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="11.5" lower_limit="2.4" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 13 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.1" lower_limit="90.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.8" lower_limit="88.5" upper_limit="99.9"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 16 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0" lower_limit="94.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="11.5" lower_limit="2.4" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 16 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0" lower_limit="94.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 13 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 13 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.1" lower_limit="90.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.8" lower_limit="88.5" upper_limit="99.9"/>
                    <measurement group_id="O5" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 16 months of age: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0" lower_limit="94.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 16 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0" lower_limit="94.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement Titer ≥1:8 and ≥1:4: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not received the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provided a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on PPP. Here, ‘Number analyzed’=participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement Titer ≥1:8 and ≥1:4: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. PPP consisted of all participants included in the trial who received at least one dose of study or control vaccine, excluding those who did not meet all protocol-specified inclusion/exclusion criteria, did not received the correct number of doses of the investigational vaccine, received a vaccine other than the one that he/she was randomized to receive, did not provided a post-dose serology sample in the proper time window, received a protocol-restricted therapy, medication or vaccine, was on systemic antibiotics within 3 days prior to study blood draw, had no serology sample or did not produce at least one valid test result, did not receive vaccine in the proper time window.</description>
          <population>Analysis was performed on PPP. Here, ‘Number analyzed’=participants with available data for specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="69.1" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="61.6" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="88.7" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" lower_limit="79.8" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="47.3" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="34.6" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135: ≥1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="56.1" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="40.8" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-HC Pre-booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-booster titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-booster titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-HC Pre-booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-booster titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-booster titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                    <measurement group_id="O2" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O3" value="66.7" lower_limit="38.4" upper_limit="88.2"/>
                    <measurement group_id="O4" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="84.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                    <measurement group_id="O3" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                    <measurement group_id="O4" value="100.0" lower_limit="91.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" lower_limit="70.3" upper_limit="92.7"/>
                    <measurement group_id="O2" value="91.5" lower_limit="81.3" upper_limit="97.2"/>
                    <measurement group_id="O3" value="81.0" lower_limit="65.9" upper_limit="91.4"/>
                    <measurement group_id="O4" value="94.9" lower_limit="82.7" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="84.1" upper_limit="98.8"/>
                    <measurement group_id="O2" value="84.5" lower_limit="72.6" upper_limit="92.7"/>
                    <measurement group_id="O3" value="90.7" lower_limit="77.9" upper_limit="97.4"/>
                    <measurement group_id="O4" value="88.1" lower_limit="74.4" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-HC Pre-vaccination Titer ≥1:8 Who Then Achieved ≥4-fold Rise in SBA-HC Titer After Vaccination: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-vaccination titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-vaccination titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post-vaccination) were reported.</description>
        <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
        <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and '0' in the number analyzed field signifies none of the participants had pre-vaccination titer ≥1:8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-HC Pre-vaccination Titer ≥1:8 Who Then Achieved ≥4-fold Rise in SBA-HC Titer After Vaccination: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-vaccination titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-vaccination titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post-vaccination) were reported.</description>
          <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and '0' in the number analyzed field signifies none of the participants had pre-vaccination titer ≥1:8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-HC Pre-booster Titer Less Than (&lt;) 1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC After Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-booster titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-booster titer was &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-HC Pre-booster Titer Less Than (&lt;) 1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC After Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Pre-booster titer was defined as titer values reported before the age of 12 months. Percentage of participants whose pre-booster titer was &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="68.1" upper_limit="94.9"/>
                    <measurement group_id="O2" value="85.7" lower_limit="71.5" upper_limit="94.6"/>
                    <measurement group_id="O3" value="92.1" lower_limit="78.6" upper_limit="98.3"/>
                    <measurement group_id="O4" value="97.0" lower_limit="84.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O2" value="93.1" lower_limit="77.2" upper_limit="99.2"/>
                    <measurement group_id="O3" value="74.1" lower_limit="53.7" upper_limit="88.9"/>
                    <measurement group_id="O4" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="47.3" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O4" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O4" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-HC Pre-Vaccination Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Vaccination: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Percentage of participants with pre-vaccination titer &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post vaccination) were reported.</description>
        <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
        <population>Analysis was performed on PPP. Here, 'Number analyzed'=participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-HC Pre-Vaccination Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Vaccination: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Percentage of participants with pre-vaccination titer &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post vaccination) were reported.</description>
          <population>Analysis was performed on PPP. Here, 'Number analyzed'=participants with available data for specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="45.9" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="76.3" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="23.1" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="18.1" upper_limit="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers (GMTs): Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
        <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months, Group 3: at the age of 5 months</time_frame>
        <population>Primary series PPP. Here, 'Number analyzed’=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers (GMTs): Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
          <population>Primary series PPP. Here, 'Number analyzed’=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="16.3" lower_limit="11.9" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="10.7" upper_limit="20.4"/>
                    <measurement group_id="O2" value="16.1" lower_limit="11.3" upper_limit="23.1"/>
                    <measurement group_id="O4" value="9.8" lower_limit="6.9" upper_limit="13.8"/>
                    <measurement group_id="O5" value="2.4" lower_limit="2.0" upper_limit="2.9"/>
                    <measurement group_id="O6" value="2.5" lower_limit="2.1" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="103.1" lower_limit="72.7" upper_limit="146.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.6" lower_limit="69.9" upper_limit="147.7"/>
                    <measurement group_id="O2" value="93.3" lower_limit="63.9" upper_limit="136.2"/>
                    <measurement group_id="O4" value="40.2" lower_limit="27.1" upper_limit="59.6"/>
                    <measurement group_id="O5" value="2.3" lower_limit="1.9" upper_limit="2.8"/>
                    <measurement group_id="O6" value="2.3" lower_limit="2.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="17.8" lower_limit="12.8" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" lower_limit="25.6" upper_limit="44.5"/>
                    <measurement group_id="O2" value="39.3" lower_limit="29.5" upper_limit="52.4"/>
                    <measurement group_id="O4" value="3.3" lower_limit="2.6" upper_limit="4.0"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.9" upper_limit="3.0"/>
                    <measurement group_id="O6" value="2.3" lower_limit="2.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="23.4" lower_limit="17.2" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="39.4" upper_limit="65.6"/>
                    <measurement group_id="O2" value="47.4" lower_limit="36.6" upper_limit="61.5"/>
                    <measurement group_id="O4" value="3.7" lower_limit="2.9" upper_limit="4.7"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.9" upper_limit="3.0"/>
                    <measurement group_id="O6" value="2.2" lower_limit="2.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Groups 2 and 7: at the age of 16 months</time_frame>
        <population>Booster PPP. Here, ‘Number analyzed’=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Booster PPP. Here, ‘Number analyzed’=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" lower_limit="39.9" upper_limit="87.2"/>
                    <measurement group_id="O3" value="98.2" lower_limit="66.1" upper_limit="145.9"/>
                    <measurement group_id="O4" value="151.1" lower_limit="102.2" upper_limit="223.4"/>
                    <measurement group_id="O5" value="2.7" lower_limit="2.1" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="76.1" lower_limit="50.5" upper_limit="114.7"/>
                    <measurement group_id="O6" value="2.8" lower_limit="2.2" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.5" lower_limit="178.5" upper_limit="412.9"/>
                    <measurement group_id="O3" value="179.9" lower_limit="112.1" upper_limit="288.6"/>
                    <measurement group_id="O4" value="641.8" lower_limit="436.4" upper_limit="944.1"/>
                    <measurement group_id="O5" value="2.8" lower_limit="2.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="272.9" lower_limit="188.2" upper_limit="395.7"/>
                    <measurement group_id="O6" value="2.8" lower_limit="2.2" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.0" lower_limit="171.2" upper_limit="373.9"/>
                    <measurement group_id="O3" value="216.7" lower_limit="156.3" upper_limit="300.3"/>
                    <measurement group_id="O4" value="396.3" lower_limit="278.3" upper_limit="564.3"/>
                    <measurement group_id="O5" value="2.3" lower_limit="1.9" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="469.5" lower_limit="351.2" upper_limit="627.6"/>
                    <measurement group_id="O6" value="2.3" lower_limit="1.9" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.7" lower_limit="244.0" upper_limit="518.6"/>
                    <measurement group_id="O3" value="306.4" lower_limit="210.9" upper_limit="445.1"/>
                    <measurement group_id="O4" value="384.5" lower_limit="267.1" upper_limit="553.7"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.8" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="685.9" lower_limit="507.1" upper_limit="927.7"/>
                    <measurement group_id="O6" value="2.2" lower_limit="1.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on PPP. Here, 'Number analyzed'=participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement Geometric Mean Titers: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC.</description>
          <population>Analysis was performed on PPP. Here, 'Number analyzed'=participants with available data for specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="9.5" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="39.9" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="4.8" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.9" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With ≥4-fold Rise in SBA-HC Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Percentage of participants with ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months), Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6, and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-fold Rise in SBA-HC Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Percentage of participants with ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6, and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="71.7" upper_limit="92.4"/>
                    <measurement group_id="O2" value="85.5" lower_limit="74.2" upper_limit="93.1"/>
                    <measurement group_id="O3" value="84.9" lower_limit="72.4" upper_limit="93.3"/>
                    <measurement group_id="O4" value="97.7" lower_limit="88.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="83.0" upper_limit="98.1"/>
                    <measurement group_id="O2" value="95.3" lower_limit="86.9" upper_limit="99.0"/>
                    <measurement group_id="O3" value="83.0" lower_limit="70.2" upper_limit="91.9"/>
                    <measurement group_id="O4" value="97.8" lower_limit="88.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="72.1" upper_limit="92.5"/>
                    <measurement group_id="O2" value="92.1" lower_limit="82.4" upper_limit="97.4"/>
                    <measurement group_id="O3" value="82.7" lower_limit="69.7" upper_limit="91.8"/>
                    <measurement group_id="O4" value="93.3" lower_limit="81.7" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="85.4" upper_limit="98.9"/>
                    <measurement group_id="O2" value="85.7" lower_limit="74.6" upper_limit="93.3"/>
                    <measurement group_id="O3" value="90.4" lower_limit="79.0" upper_limit="96.8"/>
                    <measurement group_id="O4" value="86.7" lower_limit="73.2" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise (GMFR) in SBA-HC Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3 and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months), Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, ‘Number analyzed’=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6 and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) in SBA-HC Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-HC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, ‘Number analyzed’=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6 and 7, as pre-specified in protocol.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="5.8" upper_limit="11.8"/>
                    <measurement group_id="O2" value="12.0" lower_limit="8.0" upper_limit="18.0"/>
                    <measurement group_id="O3" value="16.9" lower_limit="10.9" upper_limit="26.0"/>
                    <measurement group_id="O4" value="24.5" lower_limit="17.4" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="13.8" upper_limit="26.6"/>
                    <measurement group_id="O2" value="21.7" lower_limit="15.6" upper_limit="30.1"/>
                    <measurement group_id="O3" value="17.1" lower_limit="11.1" upper_limit="26.3"/>
                    <measurement group_id="O4" value="25.0" lower_limit="18.6" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.2" upper_limit="12.2"/>
                    <measurement group_id="O2" value="14.3" lower_limit="10.7" upper_limit="19.2"/>
                    <measurement group_id="O3" value="10.6" lower_limit="7.5" upper_limit="14.8"/>
                    <measurement group_id="O4" value="17.3" lower_limit="11.8" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="9.1" upper_limit="16.4"/>
                    <measurement group_id="O2" value="15.1" lower_limit="10.6" upper_limit="21.7"/>
                    <measurement group_id="O3" value="13.1" lower_limit="9.2" upper_limit="18.7"/>
                    <measurement group_id="O4" value="16.0" lower_limit="11.2" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Titer ≥1:8 and ≥1:128: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
        <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
        <population>Primary series PPP. Here, 'Number analyzed'=participants with available data for specified categories and '0' in number analyzed field signifies none of participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Titer ≥1:8 and ≥1:128: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
          <population>Primary series PPP. Here, 'Number analyzed'=participants with available data for specified categories and '0' in number analyzed field signifies none of participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="52.6" lower_limit="40.8" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 5 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="34.2" lower_limit="23.7" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="37.8" upper_limit="62.2"/>
                    <measurement group_id="O2" value="54.5" lower_limit="42.8" upper_limit="65.9"/>
                    <measurement group_id="O4" value="43.6" lower_limit="30.3" upper_limit="57.7"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O6" value="2.9" lower_limit="0.1" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 7 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" lower_limit="20.9" upper_limit="43.6"/>
                    <measurement group_id="O2" value="37.7" lower_limit="26.9" upper_limit="49.4"/>
                    <measurement group_id="O4" value="21.8" lower_limit="11.8" upper_limit="35.0"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O6" value="2.9" lower_limit="0.1" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="93.4" lower_limit="85.3" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 5 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="92.1" lower_limit="83.6" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="88.0" upper_limit="99.1"/>
                    <measurement group_id="O2" value="94.8" lower_limit="87.2" upper_limit="98.6"/>
                    <measurement group_id="O4" value="91.2" lower_limit="80.7" upper_limit="97.1"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.1" upper_limit="13.5"/>
                    <measurement group_id="O6" value="8.6" lower_limit="1.8" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 7 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="86.0" upper_limit="98.4"/>
                    <measurement group_id="O2" value="93.5" lower_limit="85.5" upper_limit="97.9"/>
                    <measurement group_id="O4" value="80.7" lower_limit="68.1" upper_limit="90.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="O6" value="5.7" lower_limit="0.7" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="98.7" lower_limit="92.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 5 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="81.6" lower_limit="71.0" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="90.2" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.3" upper_limit="100.0"/>
                    <measurement group_id="O4" value="82.1" lower_limit="69.6" upper_limit="91.1"/>
                    <measurement group_id="O5" value="38.5" lower_limit="23.4" upper_limit="55.4"/>
                    <measurement group_id="O6" value="37.1" lower_limit="21.5" upper_limit="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 7 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="77.3" upper_limit="94.0"/>
                    <measurement group_id="O2" value="92.2" lower_limit="83.8" upper_limit="97.1"/>
                    <measurement group_id="O4" value="46.4" lower_limit="33.0" upper_limit="60.3"/>
                    <measurement group_id="O5" value="15.4" lower_limit="5.9" upper_limit="30.5"/>
                    <measurement group_id="O6" value="17.1" lower_limit="6.6" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 5 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100.0" lower_limit="95.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 5 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="96.1" lower_limit="88.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 7 months of age: ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="93.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="80.4" lower_limit="67.6" upper_limit="89.8"/>
                    <measurement group_id="O5" value="13.2" lower_limit="4.4" upper_limit="28.1"/>
                    <measurement group_id="O6" value="14.3" lower_limit="4.8" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 7 months of age: ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="90.1" upper_limit="99.7"/>
                    <measurement group_id="O2" value="94.8" lower_limit="87.2" upper_limit="98.6"/>
                    <measurement group_id="O4" value="66.1" lower_limit="52.2" upper_limit="78.2"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O6" value="5.7" lower_limit="0.7" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-BR Titer ≥1:8 and ≥1:128: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Groups 2 and 7: at the age of 16 months</time_frame>
        <population>Booster PPP. Here, 'Number analyzed'=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-BR Titer ≥1:8 and ≥1:128: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Booster PPP. Here, 'Number analyzed'=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 13 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="67.6" upper_limit="89.8"/>
                    <measurement group_id="O3" value="96.1" lower_limit="86.5" upper_limit="99.5"/>
                    <measurement group_id="O4" value="95.2" lower_limit="83.8" upper_limit="99.4"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 13 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="55.9" upper_limit="81.2"/>
                    <measurement group_id="O3" value="88.2" lower_limit="76.1" upper_limit="95.6"/>
                    <measurement group_id="O4" value="90.5" lower_limit="77.4" upper_limit="97.3"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 16 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="81.4" lower_limit="69.1" upper_limit="90.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 16 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="74.6" lower_limit="61.6" upper_limit="85.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 13 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="83.0" upper_limit="98.1"/>
                    <measurement group_id="O3" value="88.7" lower_limit="77.0" upper_limit="95.7"/>
                    <measurement group_id="O4" value="100.0" lower_limit="91.8" upper_limit="100.0"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 13 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="83.0" upper_limit="98.1"/>
                    <measurement group_id="O3" value="86.8" lower_limit="74.7" upper_limit="94.5"/>
                    <measurement group_id="O4" value="97.7" lower_limit="87.7" upper_limit="99.9"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 16 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="98.3" lower_limit="90.9" upper_limit="100.0"/>
                    <measurement group_id="O6" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 16 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="96.6" lower_limit="88.3" upper_limit="96.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 13 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="91.6" upper_limit="100.0"/>
                    <measurement group_id="O5" value="66.7" lower_limit="44.7" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 13 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" lower_limit="85.1" upper_limit="98.9"/>
                    <measurement group_id="O3" value="94.2" lower_limit="84.1" upper_limit="98.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="91.6" upper_limit="100.0"/>
                    <measurement group_id="O5" value="37.5" lower_limit="18.8" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 16 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O6" value="73.9" lower_limit="51.6" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 16 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="96.6" lower_limit="88.3" upper_limit="99.6"/>
                    <measurement group_id="O6" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 13 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.0" lower_limit="89.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.4" upper_limit="99.9"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 13 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="94.1" lower_limit="83.8" upper_limit="98.8"/>
                    <measurement group_id="O4" value="95.2" lower_limit="83.8" upper_limit="99.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 16 months of age ≥1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O6" value="17.4" lower_limit="5.0" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 16 months of age ≥1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="98.3" lower_limit="90.9" upper_limit="100.0"/>
                    <measurement group_id="O6" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-BR Titer ≥1:8 and ≥1:128: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on PPP. Here, 'Overall number of participant analyzed'=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-BR Titer ≥1:8 and ≥1:128: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR.</description>
          <population>Analysis was performed on PPP. Here, 'Overall number of participant analyzed'=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A: ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" lower_limit="48.4" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A: ≥1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" lower_limit="33.3" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="81.0" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: ≥1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="70.6" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="85.6" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: ≥1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="57.3" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135: ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135: ≥1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="74.6" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-BR Pre-Booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-booster titer was defined as titer value reported before the age of 12 months. Percentage of participants whose pre-booster titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-BR Pre-Booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-booster titer was defined as titer value reported before the age of 12 months. Percentage of participants whose pre-booster titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="33.3" lower_limit="4.3" upper_limit="77.7"/>
                    <measurement group_id="O4" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O2" value="86.4" lower_limit="65.1" upper_limit="97.1"/>
                    <measurement group_id="O3" value="77.3" lower_limit="54.6" upper_limit="92.2"/>
                    <measurement group_id="O4" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="55.4" upper_limit="82.1"/>
                    <measurement group_id="O2" value="83.0" lower_limit="69.2" upper_limit="92.4"/>
                    <measurement group_id="O3" value="81.3" lower_limit="67.4" upper_limit="91.1"/>
                    <measurement group_id="O4" value="77.8" lower_limit="60.8" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="71.7" upper_limit="93.8"/>
                    <measurement group_id="O2" value="87.2" lower_limit="74.3" upper_limit="95.2"/>
                    <measurement group_id="O3" value="82.9" lower_limit="66.4" upper_limit="93.4"/>
                    <measurement group_id="O4" value="80.6" lower_limit="62.5" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-BR Pre-Vaccination Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Vaccination: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants whose pre-vaccination titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer at the age of Month 13 (i.e. 30-days post vaccination at Month 12) were reported.</description>
        <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
        <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed= participants evaluable for this outcome measure' and 'Number analyzed'=participants with available data for specified category. In addition, '0' in number analyzed field signifies none of the participants had titer ≥1:8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-BR Pre-Vaccination Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Vaccination: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants whose pre-vaccination titer was ≥1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer at the age of Month 13 (i.e. 30-days post vaccination at Month 12) were reported.</description>
          <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed= participants evaluable for this outcome measure' and 'Number analyzed'=participants with available data for specified category. In addition, '0' in number analyzed field signifies none of the participants had titer ≥1:8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="34.3" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="68.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-BR Pre-Booster Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titers After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-booster titer was defined as titer value reported before the age of 12 months. Percentage of participants whose pre-booster titer was &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months); Group 2: 30 days post-vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-BR Pre-Booster Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titers After Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-booster titer was defined as titer value reported before the age of 12 months. Percentage of participants whose pre-booster titer was &lt;1:8 and achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 6 and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="64.0" upper_limit="88.5"/>
                    <measurement group_id="O2" value="79.2" lower_limit="65.0" upper_limit="89.5"/>
                    <measurement group_id="O3" value="95.5" lower_limit="84.5" upper_limit="99.4"/>
                    <measurement group_id="O4" value="93.8" lower_limit="79.2" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O2" value="96.8" lower_limit="83.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="83.3" lower_limit="65.3" upper_limit="94.4"/>
                    <measurement group_id="O4" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With SBA-BR Pre-Vaccination Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Vaccination: Group 5 - Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-vaccination titer was defined as titer value reported before the age of 12 months. Percentage of participants with pre-vaccination titer &lt;1:8 and who achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post-vaccination) were reported.</description>
        <time_frame>30 days post-vaccination at the age of 12 months (i.e. at the age of 13 months)</time_frame>
        <population>Analysis was performed on PPP. Here, 'Number analyzed'=participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBA-BR Pre-Vaccination Titer &lt;1:8 Who Then Achieved ≥4-Fold Rise in SBA-BR Titer After Vaccination: Group 5 - Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Pre-vaccination titer was defined as titer value reported before the age of 12 months. Percentage of participants with pre-vaccination titer &lt;1:8 and who achieved ≥4-fold rise in each meningococcal serogroups antibody titer (30 days post-vaccination) were reported.</description>
          <population>Analysis was performed on PPP. Here, 'Number analyzed'=participants with available data for specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="47.7" upper_limit="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="79.7" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" lower_limit="53.7" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="87.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With ≥4-fold Rise in SBA-BR Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants with ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP which was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post booster vaccination (i.e., at the age of 13 months); Group 2: 30 days post booster vaccination (i.e., at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6, and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-fold Rise in SBA-BR Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants with ≥4-fold rise in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP which was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6, and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="65.9" upper_limit="89.2"/>
                    <measurement group_id="O2" value="81.1" lower_limit="68.0" upper_limit="90.6"/>
                    <measurement group_id="O3" value="88.0" lower_limit="75.7" upper_limit="95.5"/>
                    <measurement group_id="O4" value="89.5" lower_limit="75.2" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="75.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="92.5" lower_limit="81.8" upper_limit="97.9"/>
                    <measurement group_id="O3" value="80.8" lower_limit="67.5" upper_limit="90.4"/>
                    <measurement group_id="O4" value="97.5" lower_limit="86.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="57.7" upper_limit="83.2"/>
                    <measurement group_id="O2" value="84.9" lower_limit="72.4" upper_limit="93.3"/>
                    <measurement group_id="O3" value="82.4" lower_limit="69.1" upper_limit="91.6"/>
                    <measurement group_id="O4" value="78.9" lower_limit="62.7" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="74.2" upper_limit="94.4"/>
                    <measurement group_id="O2" value="88.7" lower_limit="77.0" upper_limit="95.7"/>
                    <measurement group_id="O3" value="88.0" lower_limit="75.7" upper_limit="95.5"/>
                    <measurement group_id="O4" value="81.6" lower_limit="65.7" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
        <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
        <population>Primary series PPP. 'Number analyzed'=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
          <population>Primary series PPP. 'Number analyzed'=participants with available data for specified categories and '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="26.2" lower_limit="16.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="15.0" upper_limit="38.5"/>
                    <measurement group_id="O2" value="27.5" lower_limit="17.8" upper_limit="42.3"/>
                    <measurement group_id="O4" value="17.7" lower_limit="10.9" upper_limit="28.6"/>
                    <measurement group_id="O5" value="4.4" lower_limit="3.6" upper_limit="5.3"/>
                    <measurement group_id="O6" value="4.6" lower_limit="3.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="807.8" lower_limit="550.2" upper_limit="1186.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696.0" lower_limit="489.4" upper_limit="989.8"/>
                    <measurement group_id="O2" value="689.1" lower_limit="478.4" upper_limit="992.6"/>
                    <measurement group_id="O4" value="377.8" lower_limit="231.1" upper_limit="617.6"/>
                    <measurement group_id="O5" value="4.3" lower_limit="3.7" upper_limit="5.0"/>
                    <measurement group_id="O6" value="5.4" lower_limit="3.8" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="265.5" lower_limit="198.2" upper_limit="355.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.2" lower_limit="239.6" upper_limit="463.4"/>
                    <measurement group_id="O2" value="530.8" lower_limit="420.7" upper_limit="669.6"/>
                    <measurement group_id="O4" value="53.2" lower_limit="34.5" upper_limit="81.8"/>
                    <measurement group_id="O5" value="12.3" lower_limit="7.4" upper_limit="20.2"/>
                    <measurement group_id="O6" value="13.1" lower_limit="7.1" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 5 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="526.2" lower_limit="417.3" upper_limit="663.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 7 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="655.8" lower_limit="511.5" upper_limit="840.9"/>
                    <measurement group_id="O2" value="781.7" lower_limit="595.1" upper_limit="1026.7"/>
                    <measurement group_id="O4" value="120.3" lower_limit="68.8" upper_limit="210.4"/>
                    <measurement group_id="O5" value="5.9" lower_limit="4.0" upper_limit="8.7"/>
                    <measurement group_id="O6" value="5.9" lower_limit="4.1" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months; Group 2 and 7: at the age of 16 months</time_frame>
        <population>Booster PPP. Here, ‘Number analyzed’=participants with available data for specified categories and '0' in number analyzed field signifies none of participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in timeframe and pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Booster PPP. Here, ‘Number analyzed’=participants with available data for specified categories and '0' in number analyzed field signifies none of participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in timeframe and pre-specified in protocol.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.9" lower_limit="79.8" upper_limit="238.2"/>
                    <measurement group_id="O3" value="256.0" lower_limit="183.5" upper_limit="357.2"/>
                    <measurement group_id="O4" value="406.4" lower_limit="256.1" upper_limit="644.8"/>
                    <measurement group_id="O5" value="5.3" lower_limit="3.5" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="169.7" lower_limit="100.8" upper_limit="285.7"/>
                    <measurement group_id="O6" value="4.0" lower_limit="NA" upper_limit="NA">Here, 'NA' signifies that 95% confidence interval was not computable as the standard deviation of the sample was 0, since all subjects had the same value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="975.4" lower_limit="606.5" upper_limit="1568.6"/>
                    <measurement group_id="O3" value="691.7" lower_limit="387.3" upper_limit="1235.2"/>
                    <measurement group_id="O4" value="3164.8" lower_limit="2149.8" upper_limit="4659.2"/>
                    <measurement group_id="O5" value="7.3" lower_limit="4.1" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1086.0" lower_limit="766.0" upper_limit="1539.6"/>
                    <measurement group_id="O6" value="4.8" lower_limit="3.7" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.5" lower_limit="444.5" upper_limit="755.4"/>
                    <measurement group_id="O3" value="642.2" lower_limit="471.1" upper_limit="875.4"/>
                    <measurement group_id="O4" value="942.9" lower_limit="707.6" upper_limit="1256.4"/>
                    <measurement group_id="O5" value="32.9" lower_limit="15.8" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1024.0" lower_limit="778.1" upper_limit="1347.5"/>
                    <measurement group_id="O6" value="43.3" lower_limit="21.1" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 13 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1011.2" lower_limit="763.9" upper_limit="1338.6"/>
                    <measurement group_id="O3" value="769.7" lower_limit="532.6" upper_limit="1112.4"/>
                    <measurement group_id="O4" value="826.3" lower_limit="570.1" upper_limit="1197.5"/>
                    <measurement group_id="O5" value="5.8" lower_limit="4.0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135- at 16 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1389.8" lower_limit="1027.1" upper_limit="1880.5"/>
                    <measurement group_id="O6" value="6.3" lower_limit="3.9" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers in Group 5: Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers in Group 5: Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR.</description>
          <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" lower_limit="25.2" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.1" lower_limit="247.7" upper_limit="656.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.5" lower_limit="109.5" upper_limit="253.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.1" lower_limit="288.3" upper_limit="563.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise in Serum Bactericidal Assay Using Baby Rabbit Complement Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
        <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants with GMFR in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>Groups 1, 3, and 4: 30 days post booster vaccination at the age of 12 months (i.e., at the age of 13 months); Group 2: 30 days post booster vaccination at the age of 15 months (i.e. at the age of 16 months)</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6, and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise in Serum Bactericidal Assay Using Baby Rabbit Complement Titer After the Booster Vaccination: Groups 1, 2, 3, and 4 - Booster Per-Protocol Population</title>
          <description>Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by SBA-BR. Percentage of participants with GMFR in each meningococcal serogroups antibody titer (30-days post booster vaccination) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed'=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 5, 6, and 7, as pre-specified in protocol.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="9.6" upper_limit="26.0"/>
                    <measurement group_id="O2" value="21.1" lower_limit="13.0" upper_limit="34.1"/>
                    <measurement group_id="O3" value="22.3" lower_limit="15.0" upper_limit="33.3"/>
                    <measurement group_id="O4" value="32.6" lower_limit="19.8" upper_limit="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="16.3" upper_limit="43.8"/>
                    <measurement group_id="O2" value="37.9" lower_limit="24.2" upper_limit="59.5"/>
                    <measurement group_id="O3" value="27.3" lower_limit="15.3" upper_limit="48.7"/>
                    <measurement group_id="O4" value="32.0" lower_limit="18.8" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="4.2" upper_limit="8.7"/>
                    <measurement group_id="O2" value="10.0" lower_limit="6.5" upper_limit="15.3"/>
                    <measurement group_id="O3" value="7.1" lower_limit="4.8" upper_limit="10.4"/>
                    <measurement group_id="O4" value="8.6" lower_limit="5.5" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="7.2" upper_limit="14.3"/>
                    <measurement group_id="O2" value="12.8" lower_limit="9.1" upper_limit="18.1"/>
                    <measurement group_id="O3" value="19.7" lower_limit="12.1" upper_limit="32.0"/>
                    <measurement group_id="O4" value="11.1" lower_limit="7.2" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titer/Concentration to All the Antigens Contained in Pentacel Vaccines: Groups 1, 2, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
        <description>Pentacel vaccine is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined). Antibody titer to all antigens contained in pentacel vaccines (i.e., Anti-PRP, Anti-Diptheria, Anti-pertussis [pertussis toxoid [PT], pertactin [PRN], filamentous hemagglutinin [FHA], and fimbriae [FIM]], Anti-poliovirus [anti-poliovirus Type 1, Type 2 and Type 3] and anti-tetanus) were reported. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
        <time_frame>At the age of 7 months</time_frame>
        <population>Analysis was performed on primary series PPP. Here, ‘Number analyzed’=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 5, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O4">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titer/Concentration to All the Antigens Contained in Pentacel Vaccines: Groups 1, 2, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
          <description>Pentacel vaccine is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined). Antibody titer to all antigens contained in pentacel vaccines (i.e., Anti-PRP, Anti-Diptheria, Anti-pertussis [pertussis toxoid [PT], pertactin [PRN], filamentous hemagglutinin [FHA], and fimbriae [FIM]], Anti-poliovirus [anti-poliovirus Type 1, Type 2 and Type 3] and anti-tetanus) were reported. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
          <population>Analysis was performed on primary series PPP. Here, ‘Number analyzed’=participants with available data for specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 5, as pre-specified in protocol.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.3" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.1" upper_limit="6.6"/>
                    <measurement group_id="O3" value="3.2" lower_limit="2.0" upper_limit="5.3"/>
                    <measurement group_id="O4" value="5.4" lower_limit="3.1" upper_limit="9.2"/>
                    <measurement group_id="O5" value="3.8" lower_limit="1.5" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.4" upper_limit="0.8"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.4" upper_limit="0.9"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.4" upper_limit="0.8"/>
                    <measurement group_id="O5" value="0.6" lower_limit="0.4" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="51.7" upper_limit="81.6"/>
                    <measurement group_id="O2" value="66.8" lower_limit="53.2" upper_limit="83.7"/>
                    <measurement group_id="O3" value="60.5" lower_limit="49.7" upper_limit="73.7"/>
                    <measurement group_id="O4" value="61.4" lower_limit="45.8" upper_limit="82.5"/>
                    <measurement group_id="O5" value="79.2" lower_limit="61.9" upper_limit="101.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="54.4" upper_limit="83.0"/>
                    <measurement group_id="O2" value="81.6" lower_limit="67.2" upper_limit="98.9"/>
                    <measurement group_id="O3" value="69.6" lower_limit="52.8" upper_limit="91.9"/>
                    <measurement group_id="O4" value="60.9" lower_limit="47.2" upper_limit="78.7"/>
                    <measurement group_id="O5" value="93.2" lower_limit="70.5" upper_limit="123.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" lower_limit="21.3" upper_limit="47.7"/>
                    <measurement group_id="O2" value="33.7" lower_limit="24.0" upper_limit="47.2"/>
                    <measurement group_id="O3" value="36.7" lower_limit="25.0" upper_limit="53.9"/>
                    <measurement group_id="O4" value="34.5" lower_limit="21.6" upper_limit="55.1"/>
                    <measurement group_id="O5" value="52.0" lower_limit="29.6" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.8" lower_limit="110.7" upper_limit="216.5"/>
                    <measurement group_id="O2" value="177.5" lower_limit="122.3" upper_limit="257.6"/>
                    <measurement group_id="O3" value="186.8" lower_limit="117.4" upper_limit="297.3"/>
                    <measurement group_id="O4" value="194.0" lower_limit="137.0" upper_limit="274.8"/>
                    <measurement group_id="O5" value="194.4" lower_limit="111.8" upper_limit="338.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Poliovirus Type 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.9" lower_limit="157.6" upper_limit="476.0"/>
                    <measurement group_id="O2" value="696.1" lower_limit="464.1" upper_limit="1044.1"/>
                    <measurement group_id="O3" value="716.2" lower_limit="381.0" upper_limit="1346.5"/>
                    <measurement group_id="O4" value="543.9" lower_limit="303.5" upper_limit="974.5"/>
                    <measurement group_id="O5" value="327.9" lower_limit="165.4" upper_limit="650.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Poliovirus Type 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="886.3" lower_limit="604.5" upper_limit="1299.5"/>
                    <measurement group_id="O2" value="1494.5" lower_limit="1041.3" upper_limit="2145.0"/>
                    <measurement group_id="O3" value="1401.8" lower_limit="896.5" upper_limit="2192.0"/>
                    <measurement group_id="O4" value="1054.0" lower_limit="639.7" upper_limit="1736.7"/>
                    <measurement group_id="O5" value="1075.9" lower_limit="550.6" upper_limit="2102.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Poliovirus Type 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="968.0" lower_limit="606.6" upper_limit="1544.8"/>
                    <measurement group_id="O2" value="1381.4" lower_limit="845.1" upper_limit="2257.9"/>
                    <measurement group_id="O3" value="1674.7" lower_limit="962.4" upper_limit="2914.0"/>
                    <measurement group_id="O4" value="1069.3" lower_limit="689.6" upper_limit="1658.1"/>
                    <measurement group_id="O5" value="927.5" lower_limit="469.7" upper_limit="1831.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.4" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.6" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.3" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.3" lower_limit="1.1" upper_limit="1.7"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.1" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titer/Concentration to All Antigens Contained in Pentacel Vaccines: Groups 2 and 7 - Booster Per-Protocol Population</title>
        <description>Pentacel vaccine is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined). Antibody titer to all antigens contained in pentacel vaccines (i.e., Anti-PRP, Anti-Diptheria, Anti-pertussis [PT, PRN, FHA, and FIM], Anti-poliovirus [anti-poliovirus Type 1, Type 2, and Type 3], and Anti-tetanus) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>At the age of 16 months</time_frame>
        <population>Booster PPP. Here, ‘Number analyzed’=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Groups 1, 3, 4, 5, and 6, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O2">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titer/Concentration to All Antigens Contained in Pentacel Vaccines: Groups 2 and 7 - Booster Per-Protocol Population</title>
          <description>Pentacel vaccine is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined). Antibody titer to all antigens contained in pentacel vaccines (i.e., Anti-PRP, Anti-Diptheria, Anti-pertussis [PT, PRN, FHA, and FIM], Anti-poliovirus [anti-poliovirus Type 1, Type 2, and Type 3], and Anti-tetanus) were reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Booster PPP. Here, ‘Number analyzed’=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Groups 1, 3, 4, 5, and 6, as pre-specified in protocol.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="12.7" upper_limit="23.4"/>
                    <measurement group_id="O2" value="18.0" lower_limit="8.4" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.3" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.2" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.6" lower_limit="89.5" upper_limit="131.7"/>
                    <measurement group_id="O2" value="102.6" lower_limit="80.5" upper_limit="130.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" lower_limit="108.3" upper_limit="165.9"/>
                    <measurement group_id="O2" value="122.5" lower_limit="91.8" upper_limit="163.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.4" lower_limit="112.8" upper_limit="214.2"/>
                    <measurement group_id="O2" value="122.0" lower_limit="75.9" upper_limit="196.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.7" lower_limit="376.1" upper_limit="624.6"/>
                    <measurement group_id="O2" value="619.3" lower_limit="404.0" upper_limit="949.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Poliovirus Type 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2498.6" lower_limit="1900.1" upper_limit="3285.5"/>
                    <measurement group_id="O2" value="1625.6" lower_limit="853.8" upper_limit="3094.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Poliovirus Type 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3718.9" lower_limit="2922.5" upper_limit="4732.3"/>
                    <measurement group_id="O2" value="3756.1" lower_limit="2344.6" upper_limit="6017.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Poliovirus Type 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3473.8" lower_limit="2546.0" upper_limit="4739.6"/>
                    <measurement group_id="O2" value="2733.8" lower_limit="1638.6" upper_limit="4560.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.1" upper_limit="6.3"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Groups 1, 2, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
        <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F, and 23F is reported. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
        <time_frame>At the age of 7 months</time_frame>
        <population>Analysis was performed on primary series PPP. Here, 'Number analyzed’=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Group 3, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O4">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Groups 1, 2, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
          <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F, and 23F is reported. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age.</description>
          <population>Analysis was performed on primary series PPP. Here, 'Number analyzed’=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Group 3, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                    <measurement group_id="O2" value="91.2" lower_limit="76.3" upper_limit="98.1"/>
                    <measurement group_id="O3" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                    <measurement group_id="O4" value="77.8" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O5" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="85.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="95.7" lower_limit="78.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="94.4" lower_limit="72.7" upper_limit="99.9"/>
                    <measurement group_id="O5" value="85.7" lower_limit="57.2" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="95.7" lower_limit="78.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="85.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="81.3" upper_limit="99.3"/>
                    <measurement group_id="O2" value="97.1" lower_limit="84.7" upper_limit="99.9"/>
                    <measurement group_id="O3" value="91.3" lower_limit="72.0" upper_limit="98.9"/>
                    <measurement group_id="O4" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O5" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL and ≥1.0 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Groups 1, 3, 4, and 6 - Booster Series Per-Protocol Population</title>
        <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL and ≥1.0 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F and 23F is reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on booster PPP. Here, 'Number analyzed’=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Groups 2 and 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O4">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL and ≥1.0 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Groups 1, 3, 4, and 6 - Booster Series Per-Protocol Population</title>
          <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL and ≥1.0 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F and 23F is reported. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, 'Number analyzed’=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Groups 2 and 7.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: ≥0.35 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="59.3" upper_limit="93.2"/>
                    <measurement group_id="O2" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                    <measurement group_id="O3" value="84.2" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O4" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="63.9" upper_limit="95.5"/>
                    <measurement group_id="O2" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O3" value="77.8" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O4" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O2" value="85.7" lower_limit="63.7" upper_limit="97.0"/>
                    <measurement group_id="O3" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O4" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: ≥1.0 μg/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.5" lower_limit="69.6" upper_limit="98.8"/>
                    <measurement group_id="O3" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O4" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL and ≥1.0 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Group 5- Per-Protocol Population</title>
        <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL and ≥1.0 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F and 23F is reported.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Concentration ≥0.35 μg/mL and ≥1.0 μg/mL for Serotypes in Prevnar 7 or 13 Vaccine: Group 5- Per-Protocol Population</title>
          <description>Percentage of participants with anti-pneumococcal antibody concentrations ≥0.35 μg/mL and ≥1.0 μg/mL for serotypes in Prevnar 7 or 13 vaccine i.e. 4, 6B, 9V, 14, 18C, 19F and 23F is reported.</description>
          <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: ≥0.35 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="34.9" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="42.8" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: ≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibodies to All Antigens Contained in M-M-RII and VARIVAX Vaccines: Groups 1 and 6 - Booster Per-Protocol Population</title>
        <description>Antibodies responses were measured by ELISA. Antigens contained in M-M-RII: Measles, Mumps, and Rubella and in Varivax®: Varicella. Percentage of participants with anti-measles, anti-mumps, anti-rubella, and anti-varicella antibody concentration that met the respective mentioned criterion were reported: Measles: ≥255 milli-International Units per milliliter (mIU/mL); Mumps: ≥10 Antibody units per milliliter (AbU/mL); Rubella: ≥10 International Units per milliliter (IU/mL); Varicella: ≥5 glycoprotein based enzyme-linked immunosorbent assay (gpELISA) unit/mL. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on booster PPP. Here, ‘Overall number of participants analyzed’=participants evaluable for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Groups 2, 3, 4, 5, and 7, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibodies to All Antigens Contained in M-M-RII and VARIVAX Vaccines: Groups 1 and 6 - Booster Per-Protocol Population</title>
          <description>Antibodies responses were measured by ELISA. Antigens contained in M-M-RII: Measles, Mumps, and Rubella and in Varivax®: Varicella. Percentage of participants with anti-measles, anti-mumps, anti-rubella, and anti-varicella antibody concentration that met the respective mentioned criterion were reported: Measles: ≥255 milli-International Units per milliliter (mIU/mL); Mumps: ≥10 Antibody units per milliliter (AbU/mL); Rubella: ≥10 International Units per milliliter (IU/mL); Varicella: ≥5 glycoprotein based enzyme-linked immunosorbent assay (gpELISA) unit/mL. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months.</description>
          <population>Analysis was performed on booster PPP. Here, ‘Overall number of participants analyzed’=participants evaluable for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Groups 2, 3, 4, 5, and 7, as pre-specified in protocol.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles: ≥255 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps: ≥10 AbU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella: ≥10 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: ≥5 gpELISA unit/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMCs) of Antibody Titers to Tetanus Toxoid: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
        <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age. Here, '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</description>
        <time_frame>Groups 1, 2, 4, 6, and 7: at the age of 7 months; Group 3: at the age of 5 months</time_frame>
        <population>Analysis was performed on Primary series PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and ‘Number analyzed’=participants with available data for each specified categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Antibody Titers to Tetanus Toxoid: Groups 1, 2, 3, 4, 6, and 7 - Primary Series Per-Protocol Population</title>
          <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC. Primary series PPP was defined as the PPP which was used for reporting data of time points prior to 12 months of age. Here, '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</description>
          <population>Analysis was performed on Primary series PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and ‘Number analyzed’=participants with available data for each specified categories.</population>
          <units>International Units/milliliter (IU/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At age of 5 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At age of 7 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.4" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.6" upper_limit="2.2"/>
                    <measurement group_id="O4" value="1.6" lower_limit="1.3" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.3" lower_limit="1.1" upper_limit="1.7"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.1" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations of Antibodies to Tetanus Toxoid: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
        <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months. Here, '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</description>
        <time_frame>Groups 1, 3, 4, and 6: at the age of 13 months, Group 2 and 7: at the age of 16 months</time_frame>
        <population>Analysis was performed on Booster PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and 'Number analyzed'=participants with available data for specified categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O6">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Antibodies to Tetanus Toxoid: Groups 1, 2, 3, 4, 6, and 7 - Booster Per-Protocol Population</title>
          <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC. Booster PPP was defined as the PPP that was used for reporting data of time points at and after the age of 12 months. Here, '0' in number analyzed field signifies none of the participants were evaluable at that specified time point because different groups had different planned data collection time points as defined in time frame and pre-specified in protocol.</description>
          <population>Analysis was performed on Booster PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and 'Number analyzed'=participants with available data for specified categories.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At age of 13 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.8" upper_limit="2.8"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.3" upper_limit="2.2"/>
                    <measurement group_id="O5" value="0.2" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At age of 16 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.1" lower_limit="4.1" upper_limit="6.3"/>
                    <measurement group_id="O6" value="2.7" lower_limit="2.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations of Antibodies to Tetanus Toxoid: Group 5 - Per-Protocol Population</title>
        <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC.</description>
        <time_frame>At the age of 13 months</time_frame>
        <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Antibodies to Tetanus Toxoid: Group 5 - Per-Protocol Population</title>
          <description>Antibody concentrations against tetanus toxoid were measured by ELISA and expressed as GMC.</description>
          <population>Analysis was performed on PPP. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.8" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection Site Reactions</title>
        <description>Solicited injection site reactions: tenderness/pain, erythema, and swelling and were planned to be collected and reported for each vaccine separately and not planned to be collected for Rotavirus vaccine. Here, '0' in number analyzed field for MenACYW categories signifies no participant were evaluable because in Groups 6 and 7 MenACYW vaccine was not administered; for Group 5, '0' in number analyzed field signifies safety data collection was not planned for Pentacel and Hepatitis-B vaccines; for Groups 2 and 7, '0' in number analyzed field signifies safety data collection was not planned for M-M-RII and VARIVAX vaccines, as pre-specified.</description>
        <time_frame>Within 7 days post any vaccination</time_frame>
        <population>Analysis was performed on safety population that included participants who received at least 1 dose of investigation vaccine and for whom safety data were available. Here, 'Number analyzed’=participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site Reactions</title>
          <description>Solicited injection site reactions: tenderness/pain, erythema, and swelling and were planned to be collected and reported for each vaccine separately and not planned to be collected for Rotavirus vaccine. Here, '0' in number analyzed field for MenACYW categories signifies no participant were evaluable because in Groups 6 and 7 MenACYW vaccine was not administered; for Group 5, '0' in number analyzed field signifies safety data collection was not planned for Pentacel and Hepatitis-B vaccines; for Groups 2 and 7, '0' in number analyzed field signifies safety data collection was not planned for M-M-RII and VARIVAX vaccines, as pre-specified.</description>
          <population>Analysis was performed on safety population that included participants who received at least 1 dose of investigation vaccine and for whom safety data were available. Here, 'Number analyzed’=participants with available data for specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenACYW conjugate vaccine: Tenderness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW conjugate vaccine: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW conjugate vaccine: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pentacel: Tenderness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pentacel: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pentacel: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevnar or Prevnar 13: Tenderness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevnar or Prevnar 13: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevnar or Prevnar 13: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis-B: Tenderness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis-B: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis-B: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-M-RII: Tenderness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="41"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-M-RII: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="41"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-M-RII: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="41"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VARIVAX: Tenderness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="41"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VARIVAX: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="41"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VARIVAX: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="41"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic Reactions</title>
        <description>An solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the electronic case report form (eCRF). Systemic AEs were all AEs that were not injection site reactions. They, therefore, include systemic manifestations as well as localized or topical manifestations that were not associated with the vaccination site. Solicited systemic reactions included Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability.</description>
        <time_frame>Within 7 days post any vaccination</time_frame>
        <population>Analysis was done on safety population. Here, 'Number analyzed'=participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Reactions</title>
          <description>An solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the electronic case report form (eCRF). Systemic AEs were all AEs that were not injection site reactions. They, therefore, include systemic manifestations as well as localized or topical manifestations that were not associated with the vaccination site. Solicited systemic reactions included Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability.</description>
          <population>Analysis was done on safety population. Here, 'Number analyzed'=participants with available data for specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Adverse Events</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of symptom and/or onset post-vaccination. These included both serious and non-serious events.</description>
        <time_frame>Within 30 days post any vaccination</time_frame>
        <population>Analysis was performed on safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of symptom and/or onset post-vaccination. These included both serious and non-serious events.</description>
          <population>Analysis was performed on safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immediate Unsolicited AE</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of symptom and/or onset post-vaccination. These included both serious and non-serious events. Immediate Unsolicited AE were AEs reported within 30 minutes of vaccine administration.</description>
        <time_frame>Within 30 minutes post any vaccination</time_frame>
        <population>Analysis was done on safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
            <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
            <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
            <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Unsolicited AE</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of symptom and/or onset post-vaccination. These included both serious and non-serious events. Immediate Unsolicited AE were AEs reported within 30 minutes of vaccine administration.</description>
          <population>Analysis was done on safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited non-serious AEs were collected from Day 0 to Day 30 post any vaccination. SRs were collected within 7 days post any vaccination. Serious adverse events were collected throughout the trial (up to the age of 13 months for Groups 1, 3, 4, 5 and 6; up to the age of 16 months for Groups 2 and 7), i.e. 30 days after last vaccination.</time_frame>
      <desc>SR: an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF (i.e., solicited) in terms of symptom and/or onset post-vaccination. Analysis was done on safety population. In the AE section, solicited reactions Fever, Crying abnormal, Drowsiness, and Appetite lost are reported under Pyrexia, Crying, Somnolence, and Anorexia, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months</title>
          <description>Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: MenACYW Conjugate Vaccine: 12 Months</title>
          <description>Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.</description>
        </group>
        <group group_id="E6">
          <title>Group 6: Control: 2, 4, 6, and 12 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.</description>
        </group>
        <group group_id="E7">
          <title>Group 7: Control: 2, 4, 6, 12, and 15 Months</title>
          <description>Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Kawasaki's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Staphylococcal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Failure To Thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypoxic Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="52"/>
                <counts group_id="E7" subjects_affected="47" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E4" events="17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="13" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E7" events="10" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="42" subjects_affected="29" subjects_at_risk="104"/>
                <counts group_id="E2" events="46" subjects_affected="35" subjects_at_risk="102"/>
                <counts group_id="E3" events="46" subjects_affected="28" subjects_at_risk="100"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E6" events="19" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E7" events="19" subjects_affected="16" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="324" subjects_affected="59" subjects_at_risk="104"/>
                <counts group_id="E2" events="269" subjects_affected="57" subjects_at_risk="102"/>
                <counts group_id="E3" events="188" subjects_affected="48" subjects_at_risk="100"/>
                <counts group_id="E4" events="153" subjects_affected="44" subjects_at_risk="74"/>
                <counts group_id="E5" events="54" subjects_affected="24" subjects_at_risk="70"/>
                <counts group_id="E6" events="153" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E7" events="92" subjects_affected="27" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection Site Haematoma</sub_title>
                <counts group_id="E1" events="23" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="13" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="594" subjects_affected="82" subjects_at_risk="104"/>
                <counts group_id="E2" events="626" subjects_affected="83" subjects_at_risk="102"/>
                <counts group_id="E3" events="509" subjects_affected="79" subjects_at_risk="100"/>
                <counts group_id="E4" events="272" subjects_affected="57" subjects_at_risk="74"/>
                <counts group_id="E5" events="121" subjects_affected="40" subjects_at_risk="70"/>
                <counts group_id="E6" events="297" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E7" events="219" subjects_affected="39" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="185" subjects_affected="46" subjects_at_risk="104"/>
                <counts group_id="E2" events="165" subjects_affected="45" subjects_at_risk="102"/>
                <counts group_id="E3" events="135" subjects_affected="32" subjects_at_risk="100"/>
                <counts group_id="E4" events="95" subjects_affected="39" subjects_at_risk="74"/>
                <counts group_id="E5" events="38" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E6" events="90" subjects_affected="24" subjects_at_risk="52"/>
                <counts group_id="E7" events="71" subjects_affected="21" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="223" subjects_affected="86" subjects_at_risk="104"/>
                <counts group_id="E2" events="251" subjects_affected="92" subjects_at_risk="102"/>
                <counts group_id="E3" events="189" subjects_affected="88" subjects_at_risk="100"/>
                <counts group_id="E4" events="100" subjects_affected="63" subjects_at_risk="74"/>
                <counts group_id="E5" events="48" subjects_affected="48" subjects_at_risk="70"/>
                <counts group_id="E6" events="126" subjects_affected="44" subjects_at_risk="52"/>
                <counts group_id="E7" events="116" subjects_affected="42" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Pyrexia/Fever events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="61" subjects_affected="38" subjects_at_risk="104"/>
                <counts group_id="E2" events="79" subjects_affected="46" subjects_at_risk="102"/>
                <counts group_id="E3" events="66" subjects_affected="46" subjects_at_risk="100"/>
                <counts group_id="E4" events="34" subjects_affected="31" subjects_at_risk="74"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="70"/>
                <counts group_id="E6" events="32" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E7" events="42" subjects_affected="22" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="43" subjects_affected="29" subjects_at_risk="104"/>
                <counts group_id="E2" events="31" subjects_affected="21" subjects_at_risk="102"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E6" events="18" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E7" events="25" subjects_affected="21" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" events="22" subjects_affected="12" subjects_at_risk="102"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="104"/>
                <counts group_id="E2" events="46" subjects_affected="36" subjects_at_risk="102"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E4" events="19" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E6" events="23" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E7" events="20" subjects_affected="18" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="93" subjects_affected="55" subjects_at_risk="104"/>
                <counts group_id="E2" events="107" subjects_affected="65" subjects_at_risk="102"/>
                <counts group_id="E3" events="75" subjects_affected="49" subjects_at_risk="100"/>
                <counts group_id="E4" events="45" subjects_affected="36" subjects_at_risk="74"/>
                <counts group_id="E5" events="22" subjects_affected="22" subjects_at_risk="70"/>
                <counts group_id="E6" events="54" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E7" events="43" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <description>Crying/Crying abnormal events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="164" subjects_affected="78" subjects_at_risk="104"/>
                <counts group_id="E2" events="173" subjects_affected="74" subjects_at_risk="102"/>
                <counts group_id="E3" events="137" subjects_affected="77" subjects_at_risk="100"/>
                <counts group_id="E4" events="66" subjects_affected="45" subjects_at_risk="74"/>
                <counts group_id="E5" events="30" subjects_affected="30" subjects_at_risk="70"/>
                <counts group_id="E6" events="93" subjects_affected="38" subjects_at_risk="52"/>
                <counts group_id="E7" events="77" subjects_affected="35" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="142" subjects_affected="71" subjects_at_risk="104"/>
                <counts group_id="E2" events="176" subjects_affected="81" subjects_at_risk="102"/>
                <counts group_id="E3" events="137" subjects_affected="75" subjects_at_risk="100"/>
                <counts group_id="E4" events="60" subjects_affected="46" subjects_at_risk="74"/>
                <counts group_id="E5" events="30" subjects_affected="30" subjects_at_risk="70"/>
                <counts group_id="E6" events="87" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E7" events="77" subjects_affected="38" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

